CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma (HCC)
DOI 10.1055/s-0035-1559268
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB Ruf, S Berchtold, S Venturelli, I Smirnow, T Prenzel, S Henning, U Lauer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Einleitung: Oncolytic viruses represent a novel therapeutic approach (so called virotherapy) in the treatment of malignant neoplasias, employing their ability to selectively infect, replicate in and (onco-) lyse tumor cells without affecting normal tissues. Nevertheless, in monotherapy virotherapeutics were found to face various limitations in recent clinical trials. To address those limitations, epigenetic compound…
Zitieren
Zitierempfehlung
B Ruf, S Berchtold, S Venturelli, I Smirnow, T Prenzel, S Henning, U Lauer (2015) Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma (HCC). Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0035-1559268
Mit CareLit weiterarbeiten